The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | The CAR-T tsunami: an overview & brief history
Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of chimeric antigen receptor (CAR)-T cell therapy, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Dr Sadelain describes the progress CAR T-cell therapy has made, and suggests that we should aim to improve our current understanding of CAR-T mediated toxicities.
